Pyrimidine prodrugs for the treatment of viral infections and further diseases

Patent metadata

Field	Value
Publication number	US-10968184-B2
Application number	US-201716338256-A
Country	US
Kind code	B2
Filing date	Sep 28, 2017
Priority date	Sep 29, 2016
Publication date	Apr 6, 2021
Grant date	Apr 6, 2021

Abstract

This invention relates to pyrimidine prodrug derivatives, processes for their preparation, pharmaceutical compositions, and their use in therapy.

First claim

The invention claimed is:

1. A compound of formula (I)

or a pharmaceutically acceptable salt, solvate or polymorph thereof, wherein
R 1A is hydrogen or a substituted or unsubstituted C 1-3 alkyl,
R 1B is selected from, a substituted or unsubstituted C 1-3 alkyl, heterocycle, or a substituted or unsubstituted phosphoramidate, and
R 2 is a C 1-8 alkyl optionally substituted by a hydroxyl group.

2. A compound according to claim 1 wherein R 1A or R 1B are a substituted or unsubstituted phosphoramidate and wherein R 2 is a C 1-6 alkyl substituted by a hydroxyl group.

3. A compound according to claim 1 wherein R 1A or R 1B are methyl and wherein R 2 is a C 6 -alkyl substituted by a hydroxyl group.

4. A pharmaceutical composition comprising a compound of formula (I) or a pharmaceutically acceptable salt, solvate or polymorph thereof according to claim 1 together with one or more pharmaceutically acceptable excipients, diluents or carriers.

5. A compound according to claim 1 wherein R 1A and R 1B are a substituted or unsubstituted phosphoramidate and wherein R 2 is a C 1-6 alkyl substituted by a hydroxyl group.

6. A compound according to claim 1 wherein R 1A and R 1B are methyl and wherein R 2 is a C 6 -alkyl substituted by a hydroxyl group.

7. A pharmaceutical composition comprising a compound according to claim 2 together with one or more pharmaceutically acceptable excipients, diluents or carriers.

8. A pharmaceutical composition comprising a compound according to claim 5 together with one or more pharmaceutically acceptable excipients, diluents or carriers.

9. A method for treating a virus infection, comprising administering to a subject in need thereof the pharmaceutical composition according to claim 4 in an effective amount to treat the virus infection.

10. A method for treating according to claim 9 , wherein the virus infection is a hepatitis B infection.

11. A method for treating an immune disorder, comprising administering to a subject in need thereof the pharmaceutical composition according to claim 4 in an effective amount to treat the immune disorder.

12. A method for treating cancer, comprising administering to a subject in need thereof the pharmaceutical composition according to claim 4 in an effective amount to treat the cancer.

13. The compound of claim 1 selected from the group consisting of:

or a pharmaceutically acceptable salt thereof.

Assignees

• Janssen Sciences Ireland Unlimited Co

Inventors

• Guillemont Jérôme Émile Georges
• Jonckers Tim Hugo Maria
• Raboisson Pierre Jean-Marie Bernard
• Mcgowan David Craig
• Embrechts Werner Constant Johan
• Stoops Bart Henri Theresia
• Herschke Florence Marie
• Bollekens Jacques Armand Henri
• Calmus Laurent Jacques Emile

Classifications

• A61P37/02

  Immunomodulators · CPC title

• A61P37/04

  Immunostimulants · CPC title

• C07F9/6512

  having the nitrogen atoms in positions 1 and 3 · CPC title

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• C07D405/12

  linked by a chain containing hetero atoms as chain links · CPC title